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ABSTRACT

LMEA, A CONSERVED CELL-ENVELOPE PROTEIN IN MYCOBACTERIA, IS
IMPORTANT FOR ANTIBIOTIC RESISTANCE AND CELL ENVELOPE
PERMEABILITY

MAY 2020
SARAH HASSAN OSMAN
B.S. UNIVERSITY OF MASSCHUSETTS AMHERST
M.S. UNIVERSITY OF MASSCHUSETTS AMHERST
Directed by: Professor Yasu S. Morita

The cell envelope of mycobacteria is critical for the survival and virulence of pathogenic
species during infection, and its biosynthesis has been a proven drug target. Therefore, finding
new targets in the biosynthetic pathway of cell envelope components is of great interest.
Mycobacterium smegmatis is a model organism for the study of the devastating pathogen
Mycobacterium tuberculosis. Previously, lipomannan elongation factor A (LmeA) has been
identified as a cell envelope protein that is critical for the control of mannan chain length of
lipomannan (LM) and lipoarabinomannan (LAM), lipoglycan components of the cell envelope.
The deletion mutant, ∆lmeA, accumulates abnormal LM/LAM with fewer mannan residues. To
understand the importance of this protein, the antibiotic sensitivity of ∆lmeA was tested using a
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resazurin-based viability assay. We found that the lmeA deletion leads to increased sensitivities
to antibiotics such as vancomycin and erythromycin, and lmeA overexpression leads to increased
antibiotic resistance. To directly test if the increased antibiotic sensitivity is due to the defective
permeability barrier, we used an ethidium bromide uptake assay and found that ∆lmeA is more
efficient in taking up ethidium bromide in the cell. We have also found that LmeA is important
for protein stabilization under stress conditions. MptA is an α1,6-mannosyltransferase involved
in elongation of LM and LAM mannan chain. During stress conditions in the ΔlmeA mutant,
levels of MptA decrease significantly relative to wild-type. This also results in delayed doubling
time after stress, a phenotype not seen in this mutant under normal growth conditions. In
addition, the ΔlmeA mutant has differential protein expression during stress conditions relative to
ΔlmeA in log phase, or to wild-type in either condition. To help elucidate the role of LmeA at the
molecular level, binding behavior of this protein to membrane fractions was determined. In a
subcellular fractionation analysis, LmeA localizes to fractions containing plasma membrane,
which is tightly bound to cell wall layers. To test the binding of LmeA to membrane further,
LmeA was heterologously expressed in Escherichia coli, purified, and mixed M. smegmatis cell
lysate. LmeA localized to intracellular domain fractions (IMD), indicating that LmeA is capable
of localizing to fractions containing only plasma membrane. Consistent with this finding, LmeA
is capable of binding to spheroplasts in both an ELISA setting as well as in a sucrose gradient
fractionation setting. It has also been determined that ΔlmeA has a defective capsular layer with a
unique phenotype relative to other strains. We have concluded that LmeA is important for
antibiotic resistance, cell envelope permeability, capsule formation, stress response, and have
also determined its binding properties.
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Chapter 1
Introduction
1.1 Medical relevance
Mycobacteria are a medically relevant genus of bacteria. In particular, Mycobacterium
tuberculosis (M. tb), the human pathogen and main causative agent of tuberculosis, is of global
concern. M. tb has played a large role throughout history, wiping out large portions of societies
and shaping disease surveillance. The earliest evidence of M. tb infections has been found in
human remains going back as far as 5000 BCE in Peru and Egypt 1. The earliest documents
found describing tuberculosis date back 3,300 years ago in India2. Later, between the 1600s and
1800s, tuberculosis accounted for one quarter of all deaths in Europe3. Although there have been
great public health and medical advances, tuberculosis is a health issue countries continue to
battle globally. It is estimated that about one-quarter of the current global population is infected
with M. tb4 . Of this group, between 5 and 15 percent will go on to develop active tuberculosis
with the remaining percentage having dormant, non-infectious, and non-disease-causing M. tb
infections5 . These numbers translate into 10 million new, active cases each year and 1.5 million
deaths4 . The majority active M. tb infections occur in low- and middle-income countries, but the
disease is still widespread. For example, in the United States, 8,920 cases of active tuberculosis
were reported, with an estimated 13 million latent infections5 . The treatment of tuberculosis is
multi-pronged and lengthy, requiring the use of many drugs over a long period of time. Standard
treatment for non-drug resistance tuberculosis in non-HIV patients consists of a two-month
intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a four-month
phase of isoniazid and rifampicin6. Despite the global research effort and the many
advancements in understanding this pathogen, the discovery of new drugs for tuberculosis
treatment has stalled, with only one new drug meeting FDA approval in the past 40 years7. This

1

is especially concerning due to the rise in multidrug-resistance and extensively drug-resistant
tuberculosis infections8.

1.2 Cell Envelope Overview
A large part of what makes M. tb such a good pathogen is its complex and waxy cell
envelope. This multilayered barrier protects the cell from threats like antibiotics and host
defenses and can even modulate the human immune system9. In addition to providing protection
to the cell, the cell envelope is necessary to provide the rigidity and shape to these rod-shaped
microbes. The mycobacterial cell envelope is composed of several layers. The innermost layer
begins with the plasma membrane, a phospholipid bilayer. This plasma membrane is composed
of different lipids such as cardiolipin, phosphatidylethanolamine, phosphatidylinositol,
phosphatidylinositol mannosides (PIMs), and menaquinones, as well as others. Furthermore,
mycobacterial compartmentalize plasma membrane. In Mycobacterium smegmatis, the nonpathogenic and fast-growing model organism for M. tb, a lipid domain coined intracellular
membrane domain (IMD) is spatially distinct from the rest of the plasma membrane10. The IMD
contains unique metabolic enzymes often involved in cell envelope biosynthesis, and these
proteins tend to localize to the polar regions of the cell. The IMD is also dynamic, responding to
environmental stresses such as starvation11. The next layer is a thick peptidoglycan core, on par
with other gram-positive bacteria, with the periplasmic space residing underneath. This mesh of
sugars and amino acids allows the cell to maintain its shape and rigidity12 . When this
peptidoglycan layer is removed and digested by lysozyme, the cell changes shape and eventually
lyses. Moving upwards is the arabinogalactan layer. This layer is composed of galactose and
arabinose polymers and is covalently bound to the outer membrane above it, also known as the
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mycomembrane. The outer membrane is heavy in mycolic acids and abundant in glycans and
lipids like lipomannan and lipoarabinomannan, glycolipids with great significance in immune
modulations13. This membrane forms a sort of bilayer lipidic membrane, similar in structure to
the plasma membrane. Current research suggests that the inner leaflet of this layer is mostly
formed of mycolic acids while the outer leaflet of different lipidic species like trehalolipids and
possibly lipomannan and lipoarabinomannan14. These mycolic acids covalently link this layer to
the arabinogalactan layer. Finally, there is the capsule, the outermost layer made of
polysaccharides that directly interacts with the environment surrounding the microbe. The
capsular layer plays a role in variety of processes such as the formation of biofilms and host
immunity resistance15. This layer is non-covalently attached and can be visualized by electron
microscopy. The mycobacterial capsule is composed of uncharged polysaccharides such as αglucan, arabinomannan, and mannan. The capsule can be visualized by the mannan and glucan
binding fluorescent-conjugated lectin, Concanavalin A. The capsule plays a role in host immune
response, with host receptors recognizing α-glucan16 .
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Figure 1.1: The Mycobacterial Cell Envelope Figure taken from Pathogens and Disease, Volume 76,
Issue 4, June 201810. The mycobacterial cell envelope begins with the plasma membrane. The periplasmic
space sits between the plasma membrane and the peptidoglycan core. Moving upwards, an
arabinogalactan layer is followed by the outer membrane. The outermost layer is the capsule.
4

1.3 Biosynthesis of Cell Envelope Components
The biosynthesis of different components and layers of the mycobacterial cell envelope is
a complex process involving the use of many different enzymes and other proteins. Of relevance
to this study is the biosynthesis of phosphatidylinositol mannosides, lipomannan, and
lipoarabinomannan, major components of the plasma membrane.
The most abundant PIM species in M. smegmatis, the model organism for M. tb, are
AcPIM2 and AcPIM6. Production of these PIMs begin with the synthesis of phosphatidylinositol
(PI) from inositol and cytidine diphosphate diacylglycerol (CDP-DAG). This reaction requires
no energy input and is controlled by the PI synthase PgsA, which has been found to be essential
in M. smegmatis 17. From there, PI can be decorated with varying numbers of mannose residues
and fatty acid modifications. In the case of AcPIM2, PI has two mannose residues added
sequentially by PimA and PimB’ respectively18 . An acyl chain is then added to one of the
mannose residues by PatA19 . The enzymes responsible for the first two mannose additions,
PimA and PimB’, mostly likely operate on the cytoplasmic side of the plasma membrane, as
suggested by the fact that they are GDP-mannose-dependent enzymes. The formation of AcPIM6
is less clear. The mannosyltransferase(s) that form AcPIM4 from AcPIM2 is still unknown in
mycobacteria. After AcPIM4 is formed, a mannosyltransferase termed PimE drives the
production of AcPIM6 by adding a fifth mannose to AcPIM4 using polyprenol-phosphatemannose (PPM) as a mannose donor20 .
Lipomannan (LM) and lipoarabinomannan (LAM) biosynthesis begins with AcPIM4. A
lipoprotein termed LpqW has been shown to be involved in the branching point of AcPIM4 to
either AcPIM6 or LM/LAM21 . The mannan chain of AcPIM4 is elongated to 5-20 residues to
form an LM intermediate. MptA, another mannosyltransferase, elongates this α1,6 mannan chain
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to 21-34 residues22 . The protein of focus in this study, LM elongation factor A (LmeA), is
necessary for the α1,6 mannan elongation by MptA. The mannosyltransferase MptC decorates
the α1,6 mannan backbone by α1,2 mono-mannose chains.23 To form LAM, one arabinan
residue is attached to the mannan backbone. The first arabinosyltransferase is still unknown but
EmbC, an α1,3 araibonsyltransferase, elongates the primed arabinose24 . AftC and AftB are also
involved in this arabinan addition as well as arabinogalactan biosynthesis 25,26 .

Figure 1.2: Biosynthesis of Phospholipids, PIMs, and LM/LAM. Figure by Kathryn Rahlwes 27.
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1.4 Intracellular Membrane Domain
A lipid domain coined intracellular membrane domain (IMD) has been characterized in
M. smegmatis17. This is a dynamic but spatially distinct part of the plasma membrane in
mycobacteria which contains cell envelope biosynthetic reactions. Mycobacteria grow in a polar
manner, suggesting that there may be spatiotemporal control mechanisms to provide cell
envelope precursors to this area. Microscopy has shown that IMD proteins tend to localize and
be enriched in the polar regions of the cell. The IMD, or plasma membrane free of cell wall
components, is biochemically separate from plasma membrane components that are bound to cell
wall fractions (PMCW). In a sucrose gradient fractionation, IMD proteins go to unique fractions,
separate from cytoplasmic and PMCW proteins. Proteomic analysis has shown that these IMD
fractions enzymes related to the biosynthesis of PIMs, suggesting it plays a major role in PIM
metabolism. The IMD is dynamic and responsive to environmental stresses 11. The IMD localizes
specifically to the polar region where active growth is taking place. The IMD also repositions
from the poles to the sidewall during starvation or other stress conditions11 .

1.5 Spheroplasts
As previously mentioned, the mycobacterial membrane is complex and multilayered.
Spheroplasts have the mycomembrane and cell wall layers stripped off. In order to do this,
glycine is added to inhibit the biosynthesis of peptidoglycan28. Then, lysozyme is added to
remove any existing peptidoglycan. As the peptidoglycan is removed, all the layers above it are
also removed. Without this peptidoglycan exoskeleton, the resulting wall-deficient cell
transitions from a rod to a sphere. Spheroplasts are especially fragile, requiring the use of
osmotic protective media in order to keep these cells from lysing. Studies have shown that only
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the lipidic anchors of LM and LAM are left the cell envelope after spheroplasting29 . This form
of mycobacterial cells can be especially useful in characterizing plasma membrane associated
proteins.

1.6 M. smegmatis’s Relevance to M. tuberculosis
M. tb and M. smegmatis are species of bacteria within the class of actinobacteria. They
are gram-positive, rod shaped cells that grow by inserting new cell envelope material at the
poles. A defining feature of these mycobacteria are the high GC content, with M. tb measuring at
65.6% and M. smegmatis measuring at 67.4% 30. Another defining feature of these species are
their complex and multilayered cell envelope, of which the two are highly similar. M. smegmatis
is often used as the model organism to study M. tb and other pathogenic mycobacteria due to its
non-pathogenicity and fast doubling time. M. smegmatis doubles every 3-4 hours while M.
tuberculosis doubles every 24 hours. M. smegmatis shares high genome identity with M.
tuberculosis, making it a good model for study31. This study will use M. smegmatis as a model,
and all proteins mentioned in the results section have been confirmed to have homologs in M.
tuberculosis.

1.7 Previous Data and Aims of this Study
The biosynthesis of cell envelope components is a proven target in treating M.
tuberculosis infections. Ethambutol, one of the few drugs approved to treat tuberculosis, inhibits
the enzyme that polymerizes arabinose into arabinogalactan32. Isoniazid, another drug used for
treatment, inhibits the synthesis of mycolic acids33. Therefore, it is reasonable to expect that the
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next approved drug may target a protein involved in cell envelope biosynthesis, so understanding
these pathways is of importance.
Previously, it has been shown that the deletion of the pimE gene, which encodes the
enzyme responsible for the committed step in AcPIM6 formation, results in a small colony
morphology34. This small colony morphology was used to identify suppressor mutants of ∆pimE,
some of which had significantly shorter LM and LAM. After genome sequencing, it was shown
that some of these suppressor mutants had a mutation in MSMEG_5785, or lmeA. Subsequent
testing showed that LmeA is a PMCW protein and ∆lmeA results in short LM and LAM, but not
a change in colony size or doubling time35 . It was also found that in ∆lmeA under stress
conditions, MptA degradation occurs (Rahlwes KC, unpublished observations). Lastly, it was
shown that LmeA binds to phospholipids35. These previous data provide clues to LmeA’s role,
but its exact function is still unclear. This study further elucidated LmeA’s role in cell envelope
biosynthesis and includes the following chapters:
I.

Chapter 2: Impact of LmeA on Cell Envelope Integrity and Homeostasis: This
aim includes antibiotic sensitivity, cell envelope permeability, protein expression
under log and starvation conditions, and capsule staining.

II.

Chapter 3: LmeA Localization and Cell-Envelope Binding Properties: This aim
includes LmeA binding in-vivo, in-vitro, and to spheroplasts.

III.

Chapter 4: LmeA’s Role in MptA Stabilization and Possible Interactions with
ThiX: This chapter includes the characterization of ∆lmeA under stress conditions
and the investigation of the relevance of ThiX, a protein encoded by a gene in the
same operon as LmeA.
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Chapter 2
Impact of LmeA on Cell Envelope Integrity and Homeostasis
2.1 Previous Data Within This Aim
lmeA was first identified by finding suppressor mutants of ∆pimE. pimE encodes the first
committed step in phosphatidylinositol hexomannoside biosynthesis in M. smegmatis and a
knockout mutant of this gene results in a small colony morphology. This small colony morphology
was used to find suppressor mutants that restored the wild-type colony size morphology. Of the
suppressor mutants that were found, three suppressor mutants termed S1, S10, and S22 had
mutations in MSMEG_5785. This gene was later termed lmeA. These suppressor mutants were
able to restore colony size but had smaller LM and LAM. Complementation of lmeA to these
∆pimE mutants with non-functional LmeA were able to restore LM and LAM back to the WT
phenotype. ∆lmeA also showed a small LM and LAM phenotype35.

2.2 Antibiotic Sensitivity
LmeA has been predicted to be essential in M. tb and a previous study has shown that
LmeA is upregulated during mouse infection36. It has been shown that when mycobacterial cells
have short LM and LAM, antibiotic sensitivity increases 37. These facts taken together with the
short LM and LAM in the ∆lmeA mutant led us to investigate LmeA’s role in cell envelope
integrity in terms of antibiotic sensitivity. Antibiotic sensitivity was determined through a
resazurin-based assay. Resazurin is a colorimetric dye that can be used for viability doseresponse assays. As cells grow and produce reduced electron carriers, these reduced electron
carriers can reduce resazurin, which is blue, to resorufin, which is pink. The 96-well plate can
then be read at the appropriate wavelengths, and the output is run through an equation that
translates the wavelengths into percent growth relative to a positive control. The percent growth
10

is then graphed and the inhibitory concentration that inhibits 90% of growth (IC90) is calculated,
which is what is listed below in Table 1. All values were done in triplicate.
NADH/H+

NAD+, H2O

Resazurin

Resorufin

Figure 2.1: The Reduction of Resazurin As cells grows and produce reduced electron carriers
like NADH, these reduced electron carriers reduce resazurin (blue) to resorufin (pink).

Vancomycin Cefotaxime
WT
ΔlmeA

1.00 +/- 0.14

>100

0.39 +/- 0.04 9.77 +/- 2.08

ΔlmeA::Pnative-lmeA0.58 +/- 0.09 48.23 +/- 7.56
HA
ΔlmeA::Phsp60-lmeA1.90 +/- 0.29
>100
HA

Ampicillin

Clarithromycin Erythromycin

>100

0.15 +/- 0.01

0.96 +/- 0.17

70.04 +/14.77

0.05 +/- 0.01

0.12 +/- 0.01

>100

0.15 +/- 0.01

0.31 +/- 0.01

>100

0.65 +/- 0.18

2.30 +/- 0.79

WT::Phsp60-lmeA-HA 1.73+/- 0.41

>100

>100

0.71 +/- 0.38

5.85 +/- 0.9

WT::Phsp60-lmeA2.13 +/- 0.33
HA (Episomal)

>100

>100

0.25 +/- 0.05

0.92 +/- 0.21

>100

0.09 +/- 0.01

0.49 +/- 0.08

0.09 +/- 0.02

0.19 +/- 0.01

0.89 +/- 0.2

10.55 +/- 3.41

0.05 +/- 0.01

0.09 +/- 0.02

ΔpimE
S10

0.24 +/- 0.01 84.41 +/- 3.78

0.23 +/- 0.01 10.13 +/- 1.35 64.1 +/- 6.27

S10::Phsp60-lmeA0.31 +/- 0.01
HA
S22

>100

>100

0.19 +/- 0.01 9.05 +/- 1.24 45.09 +/- 1.43

Table 2.1 Antibiotic susceptibility of various strains. IC90 values of various strains treated
with a range of antibiotics at 37°C. Units in µg/ml. Green indicates increased antibiotic resistance
relative to wildtype. Red indicates increased antibiotic sensitivity relative to WT.
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Treating M. tb infections requires the use of different classes of antibiotics with some
targeting the cell envelope and others having cytoplasmic targets. For this reason, it was of
interest to test a range of antibiotics. Vancomycin is a large antibiotic that binds to Nacetylmuramic acid and N-acetylglucosamine, the building blocks of peptidoglycan, to inhibit
the crosslinking of this layer38. Cefotaxime and ampicillin are beta-lactams that inhibit cell wall
synthesis by binding to penicillin-binding proteins39. Cells with defective cell envelopes should
show increased sensitivity to these antibiotics. Clarithromycin and erythromycin are small
antibiotics with cytoplasmic targets. These two antibiotics are macrolides that bind to the 23S
ribosomal RNA of the 50S subunit of the ribosome, inhibiting the transpeptidation and
translocation step of protein synthesis40 .
∆lmeA is more sensitive to all antibiotics tested relative to WT. When lmeA is
complemented back with a native promoter to this knockout mutant, antibiotic sensitivity
decreases. This complement is able to restore antibiotic resistance in the case of ampicillin and
clarithromycin but does not fully restore in the case of vancomycin, cefotaxime, and
erythromycin. When the ∆lmeA mutant is complemented with a heat shock protein 60 promoter
granting constitutive expression, lmeA is expressed at a higher level than the native promoter,
and antibiotic resistance increases. Antibiotic resistance is completely restored in the case of
cefotaxime and ampicillin. This strain becomes even more resistant to antibiotics relative to WT
in the case of vancomycin, clarithromycin, and erythromycin. When lmeA is expressed from the
HSP60 promoter in a WT background, similarly increased levels of antibiotic resistance was
observed. The strain remains resistant to cefotaxime and ampicillin, and becomes more resistant
to vancomycin, clarithromycin, and erythromycin relative to WT. In the next strain, lmeA
expressed was increased by expressing lmeA episomally using the heat shock protein 60
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promoter in the WT background. The strain showed the highest resistance to vancomycin,
maintained resistance to beta-lactams and erythromycin, and showed increased resistance to
clarithromycin. Taken together, this data shows that the absence of LmeA leads to an increase in
sensitivity to a range of antibiotics and the complementation and overexpression of LmeA leads
to antibiotic resistance.
Because lmeA was identified through finding suppressor mutants of ∆pimE, it was of
interest to investigate how antibiotic sensitivity compares between ∆lmeA, ∆pimE, and the
suppressor mutants. Both deletion mutants show an increase in antibiotic susceptibility but
∆pimE is slightly more resistant to antibiotics compared to ∆lmeA, except in the case of
vancomycin. Interestingly, in the case of the suppressor mutants S10 and S22 which are missing
a pimE deletion and have non-functional LmeA, antibiotic sensitivity did not significantly
increase relative to either of the single knockout mutants. Complementation of lmeA back into
the S10 suppressor mutant did improve antibiotic sensitivity, even resulting in the highest
antibiotic resistance for clarithromycin and erythromycin.
Another avenue that was investigated in terms of antibiotic sensitivity was the effect of
temperature. The previous antibiotic sensitivity table was done at 30°C. It was of interest to
determine if increasing the temperature to 37°C, the temperature of the human body, would have
a differential effect on WT relative to ∆lmeA. The tables below show the results.
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Temp.
Vancomycin

Cefotaxime

Ampicillin

Clarithromycin

Erythromycin

>100

>100

0.49 +/- 0.09

3.52 +/- 1.08

>100

>100

0.14 +/- 0.01

0.82 +/- 1.03

>100

>100

0.05 +/- 0.01

0.25 +/- 0.05

>100

>100

0.15 +/- 0.01

0.96 +/- 0.17

0.39 +/-

9.77 +/-

70.04 +/0.05 +/- 0.01

0.12 +/- 0.01

0.04

2.08

14.77

0.58 +/-

48.23 +/0.15 +/- 0.01

0.31 +/- 0.01

0.09

7.56

(°C)
1.51 +/WT
0.26
1.00 +/ΔlmeA
0.11
30

ΔlmeA::Pn
0.37 +/ative-lmeA0.04
HA
1.00 +/WT
0.14
ΔlmeA

37

ΔlmeA::Pn
ative-lmeA-

>100

HA

Table 2.2: IC90s of Various Strains in 7H9 Media at 30°C vs 37°C IC90s in the presence
of various antibiotics. Units are in µg/ml.
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It is known that as the temperature increases, the fatty acid tails of phospholipids in the
plasma membrane become less rigid, and this can lead to increased membrane fluidity. This
corresponds to the general trend when looking at the above Table 2.2 When the temperature was
increased to 37°C, WT and ∆lmeA became more sensitive to antibiotics. WT maintained its
resistance to beta-lactams regardless of the temperature change. In the case of vancomycin,
cefotaxime, ampicillin, and erythromycin, ∆lmeA’s percent change in IC90 from 30°C to 37°C
was higher than WT’s. As seen before, this native promoter complement was unable to fully
restore antibiotic sensitivity. At 37°C, the complement partially recovers antibiotic resistance. At
30°C, the complement is unable to restore antibiotic resistance.
In a previous publication, I determined the antibiotic sensitivity for WT in M63 media34.
Later, for another project, I looked at antibiotic sensitivity in M63 media but this time leaving
out Tween-80, the detergent typically used in mycobacterial cultures to mimic biofilm
conditions. Table 2.3 demonstrates that adding and removing tween can drastically change
antibiotic sensitivity in WT.

M63 –
Tween

Vancomycin

Cefotaxime

Ampicillin

Clarithromycin

Erythromycin

>100

>100

>100

1.61 +/- 0.24

78.87 +/- 28.23

>100

>100

>100

>100

M63 +
15.03 +/- 3.99
Tween

Table 2.3: IC90s of Wildtype in M63 Media in the Presence and Absence of Tween80 IC90 values of wildtype treated with a range of antibiotics at 37°C. Units in µg/ml.
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Following the confirmation of the effects of Tween-80 on the antibiotic susceptibility of
wild type, the next step was to see if this trend held true for ∆lmeA. Below in Table 2.4 are the
results.

7H9-Tween

7H9 + Tween

WT

8

1.00 +/- 0.14

∆lmeA

0.4

0.39 +/- 0.04

Table 2.4: Vancomycin IC90s of WT and ∆lmeA in the Presence and Absence of
Tween-80 in 7H9 Media at 37°C. Units in µg/ml.

Using 7H9 media, tween was either added or removed and the IC90 of WT and ∆lmeA
was determined. Without tween, antibiotic resistance increases in WT. Interestingly, the presence
of tween does not make a different in IC90 in ∆lmeA as it does in WT. Tween interacts with the
outside-most layer of the cell envelope- the capsule. This led us to believe that perhaps ∆lmeA
already has a defective capsule, and so the addition tween makes no difference.
Another interesting pattern seen in Table 2.4 was that M63 was able to increase antibiotic
resistance. The last of the antibiotic sensitivity tests was to see if M63 can increase antibiotic
resistance in ∆lmeA in the same manner it does in WT.
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Vancomycin

Cefotaxime

Ampicillin

Clarithromyci
n

Erythromyci
n

WT

>100

>100

>100

1.61 +/- 0.24

78.87 +/28.23

∆lmeA

14.70 +/- 2.92

>100

>100

0.35 +/- 0.03

0.41 +/- 0.16

∆lmeA::Pnati
ve-lmeA-HA

99.60 +/17.89

>100

>100

0.61 +/- 0.02

9.51 +/- 1.64

Table 2.5: IC90s of Various Strains in M63 Media IC90 values of various strains treated
with a range of antibiotics at 37°C. Units in µg/ml.

Indeed, ∆lmeA was able to show increased resistance to antibiotics across the board when
grown in M63 media without tween at 37°C. WT became completely resistant to vancomycin,
maintained resistance to the beta-lactams, and showed increased resistance to macrolides,
erythromycin in particular. ∆lmeA became more resistant to antibiotics across the board as well,
becoming completely resistant to beta-lactams.

2.3 Cell Envelope Permeability
As shown in the previous section, ∆lmeA showed increased antibiotic sensitivity to a range
of different antibiotics relative to WT. The next step in confirming this mutant’s defective cell
envelope was to examine cell envelope permeability. Cell envelope permeability was determined
through an ethidium bromide uptake assay. Ethidium bromide binds DNA located inside of the
cell. If the cell envelope is more permeable, more ethidium bromide will bind to DNA and
fluoresce. Fluorescence excitation at 530 nanometers and the resulting emission at 590 nanometers
was measured over a time course and plotted.
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Figure 2.2: Ethidium Bromide Permeability Assay 20 µM ethidium bromide uptake
assay to measure cell envelope permeability in wildtype, ∆lmeA, and the complement
strains. Time measured in minutes. *** indicates statistical significance

∆lmeA had an increased uptake in rate and amount of ethidium bromide relative to WT
and the complement. This data is in agreement with the antibiotic sensitivity data, indicating that
∆lmeA indeed has a defective cell envelope
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Figure 2.3: Ethidium Bromide Permeability Assay Wildtype, ∆lmeA, complements,
and an overexpression strain were tested for permeability against 20 µM ethidium
bromide. OE: overexpression.

As in Figure 2.2, WT was the least permeable while ∆lmeA showed the most
permeability. Interestingly, the lmeA overexpression strain did not decrease ethidium bromide
uptake relative to WT the way the overexpression strain improved antibiotic resistance.

2.4 Capsule Visualization
In Table 2.5, WT showed an increase in antibiotic resistance in the absence of tween,
indicating that WT has an intact capsule that is disturbed by the presence of a detergent. ∆lmeA’s
IC90 was unaffected by the presence of tween, leading us to speculate that the mutant already
had a defective capsule.
To test this hypothesis, the capsule of WT and ∆lmeA was determined by the mannan and
glucan binding FITC fluorescent-conjugated lectin, Concanavalin A and visualized using
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fluorescence microscopy. No tween was used in the growing of these strains to minimize capsule
disruption. Below are representative images of capsule staining.

Fluorescence

Phase

Merge

WT

ΔlmeA

Figure 2.4: Capsule Visualization Capsules visualized using FITC-conjugated Concanavalin A
binding lectin after one second exposure.
As this data was reproducible, it is clear that ∆lmeA has a defective capsule. WT shows a
mostly polar with some sidewall staining. ∆lmeA shows capsule staining through the length of the
cell, but only on one side of the cell. This indicates that LmeA may play a role in the distribution
of mannans and glucans in the capsule layer.
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LmeA has previously been shown to be important for MptA stabilization during stress
conditions27. For this reason, we decided to investigate the capsule staining of a strain lacking
mptA to see if it has a similar phenotype. To do this, we used an anhydrotetracycline (ATC)inducible promoter to silence the mptA gene. It was also of interesting to investigate an mptA
knockdown strain in an ∆lmeA background to see which would have the dominant phenotype.

Figure 2.5: Capsule Visualization The capsules of an mptA knockdown strain and an mptA
knockdown ∆lmeA strain were visualized using Concanavalin A and fluorescent microscopy.

The ATC-inducible mptA knockdown strain showed a unique phenotype relative to WT
and ∆lmeA with no clear pattern for capsule staining. There seems to be patches with some foci
all throughout the cell as opposed to the poles as seen in WT, or one-sided staining as in ∆lmeA.
When ATC was added to the mptA knockdown ∆lmeA strain, the ∆lmeA phenotype was
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dominant, showing only sidewall staining along one side of the cell. According to this one-sided
sidewall staining, LmeA plays a unique role in capsule formation relative to MptA.

2.5 Protein Expression During Starvation
Previously, it has been shown that LmeA plays an important role during stress conditions,
including starvation27. For this reason, it was of interest to investigate general protein expression
relative to WT in log and starvation conditions. This process was started by making sucrose
gradients of WT and ∆lmeA during log phase and starvation in order to compare protein content
in the cytoplasm, the IMD, and the PMCW. In a sucrose gradient fractionation, fractions one and
two are cytoplasmic. Fractions four through six are IMD and the remaining fractions seven
through twelve are PMCW. Next, a bicinchoninic acid (BCA) assay was done in triplicate to
standardize protein content before loading onto an SDS-PAGE gel. After equal amounts of
protein were loaded onto each lane of the gel, the protein profile was visualized by silver
staining.

Table 2.6: BCA Assay for Log-Phase Sucrose Gradient Fractions Values are wavelength 562
nanometers.

Table 2.7: BCA Assay for Starvation Sucrose Gradient Fractions Values are wavelength 562
nanometers.
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L

WT ∆lmeA WT ∆lmeA WT ∆lmeA WT ∆lmeA WT ∆lmeA WT ∆lmeA
Log Log Star Star Log Log Star Star Log Log Star Star
F5 F5
F3
F3
F3
F3
F4
F4
F4 F4 F5 F5

Figure 2.6: Silver Staining of WT and ∆lmeA Fractions 3-5 Log and Starvation Blue
arrows indicate changes in specific protein bands.

The above silver staining shows differential protein expression not only between WT and
∆lmeA, but also between log and starvation phase. For fractions three through fractions five, ∆lmeA
starvation seems to show increased protein content relative to WT log phase fractions, WT
starvation fractions, and ∆lmeA log phase fractions. Although LmeA is a PMCW protein (fractions
eight through twelve in a sucrose gradient), there are still changes in specific protein content that
are pointed out by the blue arrows in the figure above.
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L

WT
Log
F6

WT ∆lmeA ∆lmeA WT WT ∆lmeA ∆lmeA WT WT ∆lmeA ∆lmeA
Star Log Star Log Star Log Star Log Star Log
Star
F6
F6
F6
F7 F7
F7 F8 F8
F8
F8
F7

Figure 2.7: Silver Staining of WT and ∆lmeA Fractions 6-8 Log and Starvation Blue arrows
indicate changes in specific protein bands.

In fractions six through eight, there are also changes in protein content between WT and
∆lmeA. In fractions six, some of the upper bands and the lower thick band are upregulated in
∆lmeA. The fractions further from the cytoplasm tend to have less protein, which is shown here
by the low protein content in fractions seven and fractions eight. Changes in specific protein
bands are indicated by the blue arrows in the figure above.
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L

WT
Log
F10

WT
Star
F10

∆lmeA
Log
F10

∆lmeA
Star
F10

Figure 2.8: Silver Staining of WT and ∆lmeA Fraction 10 Log and Starvation Blue
arrows indicate changes in specific protein bands.

As stated before, LmeA is a PMCW protein, so it was of interest to look at protein
content changes in a PMCW fraction. Fraction 10 from each sucrose gradient underwent protein
precipitation in order to visualize during silver staining. In these fractions, contrary to the pattern
seen in Figure 2.6. In Figure 2.8, ∆lmeA starvation fractions do not have more protein content
relative to the other samples. In fact, in this fraction, WT log has the most protein content.
Specific changes in bands are indicated by the blue arrows. Taken together, these figures indicate
that ∆lmeA changes the protein profile in different ways, depending on the cellular fraction
location.
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Chapter 3
LmeA Localization and Cell-Envelope Binding Properties
3.1 Previous Data Within This Aim
Understanding the binding behavior and localization of a protein can give important clues
to its function. For this reason, it is of interest to investigate the binding of LmeA. Previously, it
has been shown that LmeA binds phospholipids His-LmeA was purified from an IPTG inducible
E. coli expression vector. In an ELISA setting, LmeA was able to bind to phosphatidylinositol,
phosphatiphatidylethanolamine, and phosphatidic acid. Interestingly, LmeA was only able to
bind to these lipids in the presence of E. coli lysate. LmeA-HA was also shown to localize to
PMCW fractions in-vivo in a sucrose gradient setting 35 .

3.2 LmeA Binding in-vitro
LmeA is predicted to have a signal peptide and is secreted into periplasmic face of the
plasma membrane (Figure 3.1). Whether or not the signal peptide gets cleaved or LmeA remains
anchored to the plasma membrane is still unknown. To further investigate LmeA localization and
binding, it is of interest to determine LmeA’s localization in-vitro, when it has a “choice” to bind
to any cell envelope component as opposed to being trapped in its natural location, the
periplasm. To investigate this, His-LmeA was purified from an IPTG inducible E. coli
expression vector (Figure 3.2). The protein was purified via a nickel affinity column and eluted
using an elution buffer containing HEPES and imidazole.
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Figure 3.1: LmeA has a Predicted Signal Peptide Figure generated using SignalP 3.0. Neural
network model. Signal peptide is likely cleaved between amino acid 27 and 28.

Figure 3.2: Purification of LmeA from E. coli Expression Vector. L: Ladder, E:
Elution, FT: Flowthrough. LmeA is a 29 kDa protein indicated by the blue arrow.
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Next, this purified His-LmeA was added to WT cell lysate and incubated for half an hour
at 37°C. LmeA was also added to buffer and ran identical to the sample as a control. These
mixtures were then added to a sucrose gradient and fractionated after centrifugation. Each
fraction was then run on an SDS-PAGE gel and a Western blot was done to probe for the protein
of interest (Figure 3.4). The same lysate was used to probe for other cell envelope proteins to
serve as markers for the cytosol, the IMD, and the cell envelope.

Figure 3.3: Western Blot Localization of LmeA-HA In-vivo After Sucrose Gradient
Ultra-Centrifugation. Figure by Kathryn Rahwles35.
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Figure 3.4: Western Blot Localization of LmeA-HA in-vitro After Sucrose Gradient
Ultra-Centrifugation

LmeA showed differential localization in-vitro vs in-vivo. In-vivo, LmeA localized to
fractions seven through twelve- PMCW fractions and co-localized with the PMCW marker,
MptC. When LmeA was added to buffer and no cell lysate was present, it remained in cytosolic
fractions and co-localized with a cytosol marker, Mpa. When LmeA was mixed with lysate, it
bound to only IMD fragments and co-localized with the IMD marker, PimB’. This indicates that
only plasma membrane, and not any cell wall component, is required for binding.

3.3 LmeA Binds to Spheroplasts
To further investigate LmeA binding activity, spheroplasts were made from WT M.
smegmatis cells. Glycine was used to inhibit the production of peptidoglycan and lysozyme was
added to remove any existing peptidoglycan. Microscopy was done before and after these
additions to confirm the presence of spheroplasts (Figure 3.5).
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Figure 3.5: M. smegmatis cells before (left) and after (right) spheroplasting

Purified His-LmeA was then added to these spheroplasts and incubated for half an hour at
37°C. This mixture was then placed atop a sucrose gradient, centrifuged, and fractionated. Each
fraction was run on an SDS-PAGE gel, transferred to a membrane, and a Western blot was done
to probe for the protein of interest as well as MptC, the PMCW marker, and PimB’, the IMD
marker (Figure 3.6).

Figure 3.6: His-LmeA and MptC Localization after Spheroplast Formation
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In vitro in rod-shaped cells, LmeA localizes to fractions containing plasma membrane
free of cell wall components and migrates differentially from the PMCW marker MptC. This
indicated that only plasma membrane is necessary for LmeA binding, and that LmeA shows
differential binding from typical PMCW proteins. This spheroplast binding assay (Figure 3.6) is
a secondary confirmation of these previous findings. Indeed, LmeA was able to bind
spheroplasts and also showed differential localization from the PMCW marker. Interestingly,
PimB’, an IMD marker, was unable to be detected upon spheroplast formation.
As another confirmation that LmeA binds spheroplasts, an ELISA was done.
Spheroplasts were made and added to the bottom of the 96-well ELISA plate. To measure
background binding, a negative control of isopropanol was added in place of spheroplasts.
Purified LmeA was either mixed with untransformed E. coli lysate or not, and these mixtures
were added. After incubation, the plate was read in a spectrophotometer at 650 nanometers.
LmeA was able to bind to spheroplasts, with or without E. coli lysate although binding was more
robust in the presence of the lysate. There was also some binding in the negative control. LmeA
was able to bind to spheroplasts, with or without E. coli lysate although binding was more robust
in the presence of the lysate. There was also some binding in the negative control. LmeA was
able to bind to spheroplasts, with or without E. coli lysate although binding was more robust in
the presence of the lysate. There was also some binding in the negative control
As another confirmation that LmeA binds spheroplasts, an ELISA was done (Figure 3.7).
Spheroplasts were made and added to the bottom of the 96-well ELISA plate. To measure
background binding, a negative control of isopropanol was added in place of spheroplasts.
Purified LmeA was either mixed with untransformed E. coli lysate or not, and these mixtures
were added. After incubation, the plate was read in a spectrophotometer at 650 nanometers.
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LmeA was able to bind to spheroplasts, with or without E. coli lysate although binding was more
robust in the presence of the lysate. There was also some binding in the negative control.

LmeA + Untransformed E. coli
Lysate + Spheroplasts

LmeA +
Isopropanol

LmeA +
Spheroplasts
0

0.05

0.1

0.15

0.2

0.25

0.3

650 nm

Figure 3.7: LmeA Binds to Spheroplasts in an ELISA Setting Values read at 650 nanometers.
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Chapter 4
LmeA’s Role in MptA Stabilization and Possible Interactions with ThiX
4.1 Previous Data Within This Aim
It has previously been shown that during stress conditions, LmeA plays a role in MptA
stabilization27 . During starvation and stationary phase, MptA degrades over time in ∆lmeA while
MptA levels stay constant in WT. It has also been found that the transcription of lmeA is
upregulated during stress conditions.

4.2 ∆lmeA Has a Growth Delay After Starvation
As mentioned before, ∆lmeA does not have a growth delay under normal laboratory
conditions. Since LmeA has previously been shown to play an important role during stress, it
was of interest to determine if ∆lmeA struggles to recover after stress conditions. To do so, we
grew WT and ∆lmeA to log phase, pelleted, washed, and resuspended in phosphate-buffered
saline (PBS), starved for 24 hours, and placed back into 7H9 Middlebrook media to allow a
chance for recovery. Optical density (OD) was measured every few hours to monitor growth
(Figure 4.1).
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Experimental culture
grown to log phase

Spin down,
wash,
resuspend in PBS

Starve
for 24
Hours

0-2 Hours

4-6 Hours

Spin down,
resuspend in
7H9

Monitor
OD

300

% Change in OD600

250

200
150
100
50
0
2-4 Hours
WT

6-9 Hours

9-20 Hours

∆lmeA

Figure 4.1: ∆lmeA Has a Growth Lag After Starvation Percent change calculated
with the following equation: % change = [OD2-OD1]/OD1
∆lmeA did not grow at all for the first two hours after starvation. From two hours to six
hours, WT and ∆lmeA grew at the same rate. From six to nine hours, ∆lmeA lagged in growth
behind WT. Finally, between nine and twenty hours, ∆lmeA not only caught up in growth rate,
but actually surpassed WT in growth. This data shows that ∆lmeA has a lag in growth that only
occurs after stress.
OD is not the most reliable method to measure cell viability as cell debris and other
factors can increase optical density, artificially inflating the growth rate. As a secondary
confirmation, this recovery growth curve was done in a different format. Instead of using OD to
monitor growth, resazurin was used to measure cell viability (Figure 4.2).
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Figure 4.2: ∆lmeA Has a Growth Lag after Starvation In the photo on the right, the orange
box indicates ∆lmeA replicates. The blue box indicates WT replicates. The green box indicates a
negative control containing only media and resazurin. Photo taken at the 1.5 hour mark. On the
left, y-axis shows percent growth normalized to WT.
These results show that ∆lmeA indeed does have a growth lag after a twenty-four-hour
starvation period. When using the OD values from the spectrophotometer to read the 96-well
plate, these values are converted to percent viability using an equation that requires a no-drug
control. Since this is not a dose response assay, there is no no-drug control and instead, WT’s
average OD value was used for this number since WT’s growth rate represents the non-variable
growth rate. In other words, ∆lmeA was normalized to WT. It takes three hours for ∆lmeA to
return to a normal growth rate. This can be visually seen in right panel of Figure 4.2, where
∆lmeA is much bluer than WT, indicating less growth.
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4.3 Investigating LmeA as a Possible Thioredoxin Reductase
lmeA shares an operon with one other gene- MSMEG_5786. According to bioinformatics,
this gene encodes a putative thioredoxin. Thioredoxins are small redox proteins that are present in
nearly all organisms. Thioredoxins operate by reducing disulfide bridges between cysteines in
other proteins. They are typically characterized by their CXXC amino acid motif and have a
characteristic thioredoxin fold in their tertiary structure. MSMEG_5786 (thiX) is 465 base pairs
long and encodes a protein that 16260.6 daltons. thiX is well conserved in mycobacteria, with the
characteristic CXXC motif present throughout M. tuberculosis, M. smeg, M. leprae, M. bovis, and
M. marinum (Figure 4.3). The ortholog in M. tb is Rv0816c.
Operons are two or more genes that share the same promoter and are transcribed
simultaneously as one large mRNA. Genes are typically grouped in operons when they encode
proteins that share a common purpose. Because of this coupled with the fact that LmeA has been
shown to play a role in stress response, it is of interest for us to investigate LmeA’s relation to
ThiX.
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Figure 4.3: thiX is a Conserved Gene Throughout Mycobacteria Top panel shows
ThiX’s location in the operon. Bottom panel shows homology between species of
mycobacteria. Top panel generated via Mycobrowser.com. Bottom panel generated by
NCBI Protein Blast. Red box indicates conserved CXXC motif that is characteristic of
thioredoxins.

One possible hypothesis is that LmeA acts as a thioredoxin reductase, reducing ThiX.
Going off this theory, it is possible that ThiX is responsible for degrading MptA in ∆lmeA during
stress conditions. Interestingly, MptA has well conserved cysteine residues that could possibly be
forming disulfide bridges for this thioredoxin to reduce (Figure 4.4).
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Figure 4.4: MptA has Conserved Cysteine Residues Throughout Mycobacteria Figure
generated using NCBI Protein BLAST. Boxes indicate conserved cysteines residues that could
form possible disulfide bridges.

To investigate this, we decided that two new strains should be made: lmeA-HA-∆thiX and
∆lmeA-∆thiX. These strains can be used for a variety of assays to check for changes in LmeA
localization and MptA levels during stress conditions. The first step was to design primers for
HiFi cloning and amplify upstream and downstream of the genes of interest using polymerase
chain reactions (PCR).

38

Figure 4.5: PCR Amplification of Upstream and Downstream
Genes of Interest L: Ladder. Lanes 1, 2, 3: lmeA upstream, 952 bp
expected size. Lanes 4, 5, 6: thiX downstream, 1034 bp expected size.
Lanes 7, 8, 9: thiX upstream, 1020 bp expected size.

After successful PCR amplification, the fragments were purified via PCR cleanup and the
proper fragments were inserted into a digested vector via HiFi cloning according to the construct
wanted. This ligated plasmid was then heat shocked into competent Escherichia coli cells and
grown on lysogeny broth (LB) plates containing hygromycin to select for the plasmid containing
a hygromycin resistant cassette. Colonies were picked and grown in TBK liquid medium
planktonically at 37°C overnight. These candidate plasmids were purified from the cells and
digested with HindIII restriction enzyme to confirm the construct.
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Figure 4.6: HindIII Restriction Enzyme Digest of Candidate
Plasmids Top Panel: ∆lmeA-∆thiX candidates, expected size: 3163 bp
& 6747 bp. Plasmid #2 chosen and sent for sequencing. Bottom Panel:
lmeA-HA-∆thiX candidates. Expected size: 3163 bp, 5729 bp. Plasmid
#1 chosen and sent for sequencing.

Candidate plasmids showing the proper band sizes after restriction enzyme digest were
sent for Sanger sequencing for secondary confirmation and both plasmids came back as the
confirmed construct. As of this thesis being written, only ∆lmeA-∆thiX has been successfully
electroporated into electrocompetent M. smegmatis cells. The colonies from electroporation were
confirmed for the double crossover event via sucrose sensitivity and hygromycin resistance and
frozen stock was made. Genomic DNA was extracted, and primers were designed outside the
inserted region to confirm the strain. The PCR came out successfully and two identical strains
were confirmed to be our constructs. No testing has yet been done on this strain.
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Figure 4.7: PCR Amplification of Extracted Genomic DNA to
Confirm Double Knockout Strain L: Ladder. Lanes 1 & 2: Upstream
fragment, expected size 1057 bp. Lanes 3 & 4: Primer set #1 to amplify
downstream fragment, expected size 1012 bp. Lanes 5 & 6: Primer set
#2 to amplify downstream fragment, expected size 1134 bp. Lanes 7 &
8: Primer set #3 to amplify downstream fragment, expected size 835 bp.

An AMB Master’s student, Audrey Della Valle, has cloned thiX into an E. coli
expression vector and successfully purified ThiX. I am in possession of purified LmeA. LmeA
will be tested for thioredoxin reductase activity by testing to see if the protein is able to reduce
5,5'-dithiobis-(2-nitrobenzoic acid) using NADPH as a source of electrons. ThiX will be tested
for thioredoxin activity against insulin.
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Chapter 5
Discussion and Future Directions
This study aimed to further characterize LmeA by investigating antibiotic sensitivity, cell
envelope permeability, protein expression during different conditions, capsule staining, binding,
and its interactions with other proteins. Although this study made advances in the
characterization of this protein, LmeA’s exact function remains unclear.
It is interesting to note that although the suppressor mutants (∆pimE with a point
mutation in lmeA rendering it non-functional) restore colony size, the suppressor mutants do not
recover in any other aspect. They are still sensitive to antibiotics, still more permeable to
ethidium bromide relative to wildtype, and still have shorter lipomannan and
lipoarabinomannan35. Perhaps it would be of interest to further study the relationship between
this restored colony size with these altered phenotypes- why only colony size is restored when
seemingly all other tested phenotypes do not recover. It is also interesting to note that these
suppressor mutants do not become more sensitive to antibiotics relative to ∆pimE or ∆lmeA. One
would assume that not having both of these functional proteins would compound and exacerbate
the already defective cell envelope and increase antibiotic sensitivity. Perhaps this could be
another route of investigation.
∆lmeA became more sensitive to antibiotics. This was expected because this mutant is
unable to produce mature LM and LAM- important components for cell envelope integrity. Less
expected was the increased antibiotic resistance seen in the three overexpression strains.
Previously, it has been shown that in these overexpression strains, LM and LAM are more
abundant. This leads us to conclude that the wildtype cell envelope has room for improvementapparently increasing the abundance of LM and LAM translates into a more fortified cell
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envelope. One study showed that lmeA is upregulated upon M. tb infections in mice, and this is
in accordance with the pattern we are seeing. It is also worth noting these strains have different
responses to antibiotics, depending on the antibiotic’s target. In the lmeA overexpression strains,
antibiotic sensitivity increased at a rate higher in macrolides than antibiotics with cell envelope
targets. It is also worth noting that in the suppressor mutant strain complemented with
overexpressed lmeA, antibiotic resistance is at an all-time high for erythromycin relative to the
other strains tested. Another point to note is the difference in antibiotic sensitivity between
clarithromycin and erythromycin. They are both macrolides- in fact, clarithromycin is just the
new generation of erythromycin. Clarithromycin has been shown to be several-fold more active
in-vitro than erythromycin. This supports the trend seen in the antibiotic resistance table.
Clarithromycin resistance only increases six-fold at its peak while erythromycin increases tenfold at its peak. Another point to be made with this antibiotic sensitivity data is its relation a
previously done transposon mutagenesis. Wildtype and ∆lmeA underwent a transposon
mutagenesis assay. As one can see below in Figure 5.1, ∆lmeA had fewer insertions in
MSMEG_2584, a gene encoding a putative penicillin binding protein. This data is in accordance
with the antibiotic sensitivity data showing ∆lmeA is sensitive to beta-lactams.
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Figure 5.1: Transposon Mutagenesis Data Experiment done by Kathryn Rahlwes and analyzed
by Hiro Kado.
It is also interesting to discuss temperature’s effect on ∆lmeA. At higher temperatures, the
fatty acid tails of phospholipids in the plasma membrane become less rigid, and this can lead to
increased membrane fluidity. From 30°C to 37°C, ∆lmeA showed increased antibiotic sensitivity
by more than 2.5-fold in the case of vancomycin while WT only increased by 0.5-fold. Perhaps
the lack of LM and LAM exacerbates this membrane fluidity that follows an increase in
temperature. It is unclear why the native complement struggles to restore antibiotic resistance.
Perhaps it is the L5 integration site of the complemented lmeA gene that is responsible for this.
This issue is exacerbated at 30°C- something that is not seen at 37°C. A western blot comparing
LmeA-HA levels at these two temperatures would easily solve this question.
The presence or absence of the detergent tween did not have an effect on ∆lmeA antibiotic
sensitivity, while WT was greatly affected. Since tween only physically interacts with the capsule,
it leads us to believe that our mutant already has a defective capsule. If ∆lmeA naturally has a
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defective capsule, the disturbance from tween will not have a significant effect on antibiotic
sensitivity. The capsule staining that was done supports this hypothesis. Wildtype capsule staining
showed mostly polar with some sidewall staining. ∆lmeA had a unique phenotype that showed the
length of the sidewall being stained, but only on one side. This phenotype has been reproduced in
three separate experiments. In addition, this ∆lmeA capsule phenotype is the dominant phenotype
in an mptA knockdown-∆lmeA strain. This leads us to believe that perhaps LmeA is involved in
the distribution of mannoses and glycans in the capsule, or that it stabilizes a protein that serves
this function. Further investigation is needed into this theory.
M63 media without tween was able improve ∆lmeA’s sensitivity to various antibiotics. WT
recovered greatly in the case of vancomycin and erythromycin while ∆lmeA recovered less
significantly across the different classes of antibiotics. In accordance with all of this antibiotic
sensitivity data, ∆lmeA is more permeable to ethidium bromide. Taken together, this mutant has a
clearly defective cell envelope.
Protein expression in WT and ∆lmeA is different, whether in log phase or starvation. In
earlier fractions, ∆lmeA has increased protein content in starvation lanes relative to any of the other
conditions. In later fractions, this trend does not seem to hold true. This is interesting because
LmeA is a PMCW protein, localizing to fractions seven through twelve. For this reason, it was
surprising to see differences in protein content throughout the different parts of the cell. The four
sucrose gradients used for this experiment were made by three different people in the Morita lab.
I have re-made all four sucrose gradients in my hands to minimize variability in preparation. These
sucrose gradients have yet to be visualized via silver staining, but this will be a next step.
We know that LmeA is a PMCW protein because in-vivo, it localizes to PMCW fractions
in sucrose gradients. The localization and binding of a protein can give clues to a protein’s
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function, so fully investigating binding was of interest. LmeA has a signal peptide. This signal
peptide can either be cleaved, or it can remain and anchor the protein to the cell envelope; it is
unclear which is the case. To investigate, purified LmeA was added to cell lysate, incubated, ran
on a sucrose gradient, fractionated, and then ran on a Western blot. Probing for His-LmeA showed
that LmeA bound to IMD fractions, or plasma membrane free of cell wall fractions. This indicated
that LmeA has no preference for cell wall components. This could lead one to believe that the
signal peptide does not get cleaved off, and LmeA remains anchored interacting with the plasma
membrane. If the signal peptide got cleaved off, LmeA would be free to float around the periplasm,
perhaps having some interaction and thus affinity for the next layer- peptidoglycan.
An experiment that would give us a definitive answer to this question is to visualize LmeA
in-vivo under the microscope. The issue with this is that LmeA is a small, 29 kDa protein that
would not take well to a large fluorescent protein tag. LmeA is periplasmic, so using a tagged
LmeA strain to do immunofluorescence would not work. The solution to this is to remove all the
layers of the cell envelope from peptidoglycan upwards and to do immunofluorescence with a
tagged LmeA strain. We have attempted to do this, successfully forming spheroplasts in the
process but we have been unable to produce a reproducible result. If LmeA is anchored to the cell
envelope, we should see fluorescence. If LmeA’s signal peptide gets chopped off, then LmeA
should float away into the media upon the removal of peptidoglycan. This is a future direction that
needs to be finished.
One clue that is in agreement with all previous binding data is that LmeA binds
spheroplasts. Spheroplasts contain just plasma membrane. LmeA binds spheroplasts both in a
sucrose gradient setting and an ELISA setting. It is interesting to note that even in spheroplasts
where there is no cell wall, LmeA still migrates to different fractions from our PMCW marker
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MptC. It is also interesting to note that based upon this experiment and other experiments done
for a different project, IMD proteins seems to disappear upon the formation of a spherical cell.
This could branch out to form a small side project- whether or not the IMD is shape dependent.
In the ELISA-based spheroplast binding assay, it was interesting to see that LmeA could bind
spheroplasts with or without E. coli lysate, although binding was better with it. It was also
interesting to note that untransformed E. coli lysate was used and binding still occurred. Previous
data has shown that in order for LmeA to bind to phospholipids, transformed E. coli was
required.
LmeA has previously been shown to be important for MptA stabilization during stress
conditions. Consistent with this data is the above growth recovery curve after starvation. ∆lmeA
does not have a growth lag when grown in normal conditions. This phenotype is specific to stress.
Perhaps the lack of MptA during these conditions leads to a decrease in doubling rate. An
experiment to test this would be to see if ∆mptA has a growth lag during starvation. If it does and
it is similar to the timing of LmeA, this would tell us that this growth lag is an MptA dependent
phenomenon. If it does not have a growth lag, it would tell us this phenotype is specific to LmeA.
Previous data has shown that an mptA knockdown strain does not have a growth lag.
One possibility of LmeA’s function is that it is a thioredoxin reductase. This speculation
was partially generated based on the fact that LmeA shares an operon with thioredoxin. Genes that
share an operon typically operate in the same system. In addition, MptA has conserved cysteine
residues that could possibly form disulfide bridges. Perhaps LmeA protects MptA from ThiXmediated degradation.
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Figure 5.2: Model for LmeA as a Possible Thioredoxin Reductase In this
hypothesis, under active growth, LmeA interacts with MptA to produce full length
LM/LAM. During stress conditions, LmeA protects MptA from stress-inducedthioredoxin-mediated degradation, allowing for the biosynthesis of mature
LM/LAM. In ∆lmeA, ThiX degrades MptA, resulting in immature LM/LAM.

A few experiments have to take place for this to above model to be confirmed. First,
purified LmeA needs to be tested for thioredoxin reductase activity. Second, purified ThiX needs
to be tested for thioredoxin activity. Both proteins have been expressed and purified from E. coli
expression vectors, so the assay just needs to be done. After this, a next step would be to use the
∆lmeA-∆thiX strain made in this study to see if MptA degradation occurs during starvation. If ThiX
is responsible for MptA’s degradation during starvation in ∆lmeA, then no degradation should
occur during starvation in this double knockout strain. Another possible step could be to get the
crystal structure of MptA to confirm these possible disulfide bridges. MptA currently does not
have crystal structure due to the fact that it is a membrane protein, which are infamous for being
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difficult to accurately crystallize. Preliminary data may support this hypothesis. An easier way to
test for disulfide bridges would be to use a commercially available fluorescent dye that binds to
disulfide bonds. A previous student performed thiol trapping on MptA in the ∆lmeA strain and
showed that MptA contained no disulfide bonds relative to WT. This experiment needs to be
repeated with additional control, such as using the ∆thiX strain to see if the phenotype is the same,
confirming our hypothesis. Another experiment would be to perform thiol trapping on the ∆lmeA∆thiX strain to see if these disulfide bonds remain absent in MptA.
Another interesting future direction would be to use the lmeA-HA-∆thiX strain to see if
LmeA localization changes in the absence of ThiX. Perhaps LmeA’s sole function is to protect
MptA from degradation and if ThiX is not present, LmeA could be downregulated or its
localization could change. mRNA transcripts of lmeA for this strain could be done to check for
lmeA levels as well as a sucrose gradient to check for changes in localization. Looking back at
Figure 5.1, ∆lmeA has fewer insertions in MSMEG_5470c which encodes for molybdopterin
biosynthesis protein MoeA 1. This protein is involved in redox reactions, as is ThiX. Literature
has shown that ThiX has physical interactions with MoeA in other organisms such as E. coli, and
programs like string tie together thioredoxins with redox proteins related to MoeA.
There are many clues to LmeA’s exact function but still no smoking gun. With the purified
ThiX and the knockout strain that were made, LmeA’s role in cell envelope biosynthesis could be
determined soon.
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Chapter 6
Methods

6.1 Bacterial Strains and Growth Conditions
Wild-type (WT) M. smegmatis mc2155 (Snapper et al.1990), ΔpimE, ΔpimE::pimE41 ,
ΔlmeA, ΔlmeA::Pnative-LmeA-HA, ΔlmeA::Phsp60-LmeA-HA35 were grown in 130 rpm
planktonic conditions at 30°C or 37°C in a liquid culture of Middlebrook 7H9 manufactured by
Becton Dickinson. 7H9 was supplemented with 0.2% glycerol, 0.2% glucose, 15 mM NaCl, and
0.05% tween. Other cultures were grown in M63 minimal media, of which the recipe can be
found in Eagen et al. 201834 . Culture was grown to log phase (OD600 0.6-1). For starvation
conditions, once log phase was reached, the cultures were spun down at 4000 rpm for 5 minutes,
washed with sterile phosphate-buffered saline, spun down as described before, resuspended in
the original volume in sterile phosphate-buffered saline, and starved for 24 hours. For the
recovery assay, cultures in PBS were spun down as described above and resuspended in 7H9
complete media, as described above and OD600 was monitored.

6.2 Antibiotic Sensitivity Assay
Frozen stocks with known colony forming units (cfu) were prepared for all tested strains
by growing cells to an OD600 reading between 0.5 and 1.0 in Middlebrook 7H9 or M63, and
frozen in aliquots with a final concentration of 15% (w/v) glycerol at –80°C. In 96-well
microtiter plates, antibiotics were serially diluted in 100 μl of media and mixed with cells from
the frozen stocks to achieve the final density of 5.0 × 103 cfu/mL. The plates were incubated in a
humidity chamber either at 30 °C or 37°C. After a 24 hour 32 hour incubatiom, 20 μL of filtersterilized 0.015% (w/v) resazurin solution was added to each well to initiate colorization. After
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additional 8 hour (37°C) or 13.5 hour (30°C) incubation, the plates were read on a
spectrophotometer at 570 and 600 nm. Percent difference in cell viability between antibiotictreated and control cells was calculated using the formula: (O2 × A1 – O1 × A2)/(O2 × P1 – O1
× P2) × 100, where O1 and O2 are molar extinction coefficient of resazurin (oxidized form) at
570 and 600 nm, respectively; A1 and A2 are absorbance of test wells at 570 and 600 nm,
respectively; and P1 and P2 are absorbance of positive control well at 570 and 600 nm,
respectively. The IC90 values were calculated using OriginPro 9.1 data analysis software.

6.3 Ethidium Bromide Uptake Assay
Ethidium bromide uptake assay was done in accordance to Eagen et. Al, 201834. Briefly,
log phase (OD600 = 0.5–1.0) cells grown in 7H9 were centrifuged and pellets were resuspended
at an equal OD600 reading in 50 mM KH2PO4 (pH 7.0) and 5 mM MgSO4. Cells were then
incubated for 5 min with 25 mM glucose, transferred to an opaque, black 96-well microtiter plate
(Brand Tech Scientific), and mixed with 20 μM of ethidium bromide. Fluorescence was
measured with an excitation wavelength of 530 nm and an emission wavelength of 590 nm.

6.4 Capsule Staining
20 mL primary cultures were inoculated into Middlebrook 7H9 supplemented with 0.2%
glycerol, 0.2% glucose, 15 mM NaCl, without tween and grown at 37°C. After 3-4 days,
secondary cultures were inoculated, also without tween. After 16-18 hours, cells were pelleted at
4000 rpm for 5 minutes and resuspended in 450 µL of PBS and 50 µl of 2 mg/ml of FITCfluorescent-conjugated lectin Concanavalin A suspended in 0.1M sodium bicarbonate and
incubated for 30 minutes at 37°C. The solution was spun down at 12000 rpm for three minutes,
washed with PBS, and spun again. The final pellet was suspended in resuspended in 100 µl PBS.
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5-10 µl of this solution was pipetted onto a 1% agarose in 7H9 gel pad atop a glass slide and
visualized via fluorescent microscopy.

6.5 Silver Staining
A BCA assay was first done to determine protein content per sucrose gradient fraction.
10 µL of each sample was added to a 96 well plate. 200 µL of the Pierce BCA Protein Assay Kit
was added to each well and incubated in the dark for 30 minutes at 37°C. The plate was then read
in a spectrophotometer at 562 nm. These values were then used to standardize protein content
before silver staining. 12 µL of each sucrose gradient fraction standardized for protein content
was mixed with 4 µL of loading buffer and boiled at 95°C for five minutes. Each sample was
then loaded onto a 12% acrylamide SDS-PAGE gel and ran at 150V. The gel was incubated with
a fixative solution for 45 minutes and washed three times with Milli-Q water. The gel was then
incubated a sensitizing solution for 2 minutes and washed with water for 5 minutes. The gel was
then incubated with a silvering solution fo r45 minutes and rinsed for 20 second with water
afterwards. A developer solution was added for 6-8 minutes until the stop solution was added to
stop the reaction.

6.6 LmeA Purification
Protocol by Kathryn Rahlwes. E. coli BL21 cells transfected with pMUM 121 was
inoculated into 20 mL TBK with 100 µg/ml ampicillin and grown at 37°C overnight. 5 mL was
inoculated into 500 mL TBK and incubated at 30°C planktonically at 130 rpm until OD600
reached 0.6. A final concentration of 1 mM IPTG was added.
After 3 hours of incubation with IPTG, the culture was spun down at 8000 rpm for 10
min at 4°C. Supernatant was discarded and pellet was resuspended in 40 mL PBS and transferred
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to a 50 mL conical tube. Weight of pellet was measured. Add 1 mL of lysis buffer (see recipe
below) per 0.25 g pellet. Incubate 10 min at room temperature. Sonicate on ice for 10 sec and
repeat five times, keeping on ice in between sonications. Transfer sonicated sample to 15 mL
conical tube and centrifuge for 30 min at 4°C. Transfer supernatant and spin again. Filter
supernatant though 0.22 µM syringe filter to remove any remaining cell debris.
LmeA was purified from an E. coli IPTG inducible expression vector using a nickel
affinity column. LmeA purification materials used include Ni NTA Resin (GoldBio, H-250-25),
20 mM HEPES pH 7.5, Amicon Ultra-4, Lysis buffer (3.9 mL of 50 mM HEPES pH 7.5, 200
mM NaCl, 50 µL 100 mM PMSF in 50 mM HEPES pH 7.5, 50 µl 100 mM DTT, 500 µL 10
mg/ml Lysozyme), wash buffer (100 mM HEPES pH 7.5, 10 mM imidazole, 500 mM NaCl),
elution buffer 1 (100 mM HEPES pH 7.5, 75 mM imidazole, and elution buffer 2 (100 mM
HEPES pH 7.5, 125 mM imidazole), elution buffer 3 (100 mM HEPES pH 7.5, 250 mM
imidazole). 250 µl of bed volume of Ni NTA Resin was loaded onto a 15 ml column and washed
with 5 volumes of wash buffer. 10 mL of lysate was incubated in this overnight at 4°C while
rotating. The next day, the column was opened and the flow through was collected. Wash the
resin with 1 mL of wash buffer plus 0.05% tween. Wash three times with wash buffer without
tween. Elute penta-His-tagged-LmeA using 200 µL elution buffer 1, then elution buffer 2, then
elution buffer 3. Repeat until 15 fractions are collected. Run all samples on SDS-PAGE and
visualize with Coomassie Brilliant Blue. Fractions containing peak His-LmeA are combined,
concentrated, washed three times with 20 µM HEPES pH 7.5, and resuspended in a final volume
of 1 mL containing 20% glycerol.
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6.7 In-vitro and In-vivo Sucrose Gradient Fractionation
2.5 mL of primary cultures were inoculated into three 500 mL cultures containing 7H9
complete. After 16-18 hours of planktonic growth at 37°C, or until the OD600 reaches 0.6-1.
These cultures were then spun down at 8000 rpm for 15 minutes at 4°C. The supernatant was
poured off and the pellets were resuspended in 50 mM Hepes/NaOH (pH 7.4), spun again as
above, and resuspended in 5 ml of lysis buffer per 1 gram of wet pellet. Lysis buffer: 25 mM
Hepes (pH7.4), 20% sucrose in 25 mM Hepes, 2 mM EGTA. 1/25 volume lysis buffer of
protease inhibitor was added. 2200 psi of nitrogen gas for thirty minutes was applied to this
mixture three times to lyse cells. The lysed cell mixture was centrifuged for 4000 rpm for 10 min
at 4°C. The supernatant was removed and centrifuged as before. 1200 µL of this solution was
placed atop a 20-50% sucrose gradient and centrifuged at 35000 rpm for 6 hours at 4°C. For the
in-vitro experiment, 1 mg/mL of purified protein was added and incubated at 37°C for 30
minutes before loading onto the sucrose gradient. The gradient was then fractionated into 13
fractions and stored at 80°C.

6.8 ELISA Spheroplast Binding Assay
Either spheroplasts or isopropanol were added to the bottom of an ELISA plate. The plate
was evaporated without the lid at 37°C for 2 hours. 20 µL of hexanes was added to all wells to
block and evaporated in a fume hood for 20 minutes. 5% milk was then added for 16-19 hours at
4°C without shaking with the cover. The wells were washed twice for five minutes with 200 µL
of PBST. 10 µL of 1 mg/mL protein was added to each well and incubated for two hours at
37°C. The wells were washed with 200 µL PBST for 5 minutes at room temperature three times.
50 µL of 1:4000 penta-his primary antibody was added to each well and incubated for one hour
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at room temperature. Each well was washed with 200 µL PBST for five minutes three times. 100
µL of TMB colorization reagent was added to each well and incubated for one hour at room
temperature in the dark. The plate was then read at 650 nm.

6.9 Post-Starvation Growth Recovery Curve
WT and ∆lmeA were inoculated into 20 mL cultures containing Middlebrook 7H9
supplemented with 0.2% glycerol, 0.2% glucose, 15 mM NaCl, and 0.05% tween and grown for
3-4 days planktonically at 37°C. Secondary cultures were then innoculated and grown for 16-18
hours or until an OD600 of 0.6-1.0 was reached. The cultures were were spun down at 4000 rpm
for 5 minutes, washed with sterile phosphate-buffered saline, spun down as described before,
resuspended in the original volume in sterile phosphate-buffered saline, and starved for 24 hours.
For the recovery assay, cultures in PBS were spun down as described above and resuspended in
7H9 complete media, as described above and OD600 was monitored.

6.10 Making Spheroplasts
A secondary culture of M. smegmatis was grown at 37°C until an OD600 of 0.6-1 was
reached. Glycine was added to the culture to a final concentration of 1.2% (w/v) and incubated
for another 20-24 hours. The culture was then centrifuged at 4000 rpm for 5 minutes and washed
with Spizizen’s minimal medium (SMM), spun again above, and resuspended in SMM at the
original volume of the culture. A filter sterilized solution of 5 mg/ml lysozyme at 20% w/v and
glycine at 1.2% w/v was added. The culture was incubated for another 20-24 hours. The
formation of spheroplasts was confirmed by microscopy.

55

6.11 Polymerase Chain Reaction (PCR) Amplification
For PCR amplification to generate inserts for ligation, each tube contained the following:
12.8 µl of Pre-Mix (8.8 µL water per tube, 3.2 µl 5x Phusion HF buffer per tube, 0.4 µl 10 mM
dNTPs per tube, 0.4 µl 0.1 ng/µl genomic DNA per tube), 1 µL each of forward/reverse primer,
0.8 µL DMSO, and 0.4 µL water. After heating to 98°C, 4 µL of hot start mix was added to each
tube (3 µL water per tube, 0.8 µL 5x Phusion HF buffer per tube, 0.2 µL Phusion DNA
Polymerase per tube). The reaction continued thirty times. The resulting DNA was run on a 1%
agarose gel and visualized via ethidium bromide incubation and UV light.
For PCR amplification to confirm extracted M. smeg genomic DNA, the above
concentrations were used with an added 4 µL of extracted DNA. DNA was extracted by
incubating frozen stock for 30 minutes on a 95°C heating block. The sample was micro
centrifuged at 16000 rpm for 2 minutes and the supernatant was transferred to a new tube. 200 µl
of 24:1 (w/v) chloroform/isoamyl alchol mix was added to the sample and briefly vortexed to
extract proteins and lipids. The sample was placed on ice and 1/10 volume of 3M sodium acetate
and 2.5 volumes of ice-cold 100% ethanol was added. The sample was micro centrifuged for 5
minutes at 4°C, the supernatant was poured off, and and the pellet was air-dried until all ethanol
was evaporated. The pellet was resuspended in 100 µL milliQ water.
PCR clean-up was done with a Qiagen QIAquick Gel Extraction kit. 5 volumes of Buffer
PB was added to the sample and 3M Na-Acetate (pH 5.0) was added until sample turned yellow.
Sample was applied onto a QIAquick column and spun for 1 minute and repeated. The column
was washed with 750 µL Buffer PE and incubated for 2-5 minutes before spinning. The column
was transferred to a new tube and the DNA was eluted with pre-warmed (60°C) Buffer EB that
was incubated for 5 minutes at room temperature before spinning.
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6.12 HiFi Assembly
First the DNA concentrations of digested vector and inserts were measured using
Nanodrop. For DNA ranging from 0.03-0.2 pmol, the ratio of vector to insert was 1:2. The
following equation was used for calculations: pmols = (weight in ng) x 1000 / (base pairs x 650
daltons). After calculating and mixing the proper ratio of vector to insert, 1 volume of NEBuilder
Master Mix was added and the sample was incubated for 15 minutes at 50°C. 5 µl of this plasmid
was added to 250 µL of E. coli lab-made competent cells and placed on ice for 30 minutes. Then
the cells were heat shocked at exactly 42°C in.a water bath for 45 seconds. The sample was
placed on ice for 2 minutes and 950 µL of room temperature SOC broth was added to each tube.
The sample was incubated for 60 minutes at 37°C. 100 µL of this mixture was pipetted onto
selection plates containing the proper antibiotic and incubated overnight at 37°C. Colonies were
picked and grown in 2 ml of TBK media with proper antibiotic overnight. The cells were
pelleted and the supernatant was poured off. The pellet was resuspended in ice-cold 200 µL
Qiagen Buffer P1. 200 µL of Buffer P2 and P3 were added to the sample and inverted to mix. 50
µl chloroform was added and vortexed. The sample was spun down at 4°C and the upper phase
was transferred to a new tube. 1/10 volume 3M Na-acetate (pH 5.2) was added and DNA was
precipitated by adding 2 volumes of ice-cold ethanol and inverted to mix. Plasmid DNA was
collected by spinning at max speed at 4°C for 10 minutes and the supernatant was removed. 1
mL of ice-cold 70% ethanol was added to the pellet and the tube was inverted. The sample was
spun down at max speed for 2 minutes at 4°C and the supernatant was removed thoroughly using
an aspirator. The pellet was air dried until the pellet looked translucent. The pellet was
resuspended in Buffer EB. The plasmid DNA was then used for restriction enzyme digestion and
candidate plasmids were sent for Sanger sequencing.

57

BIBLIOGRAPHY

1. Gerszten PC, Gerszten E, Allison MJ. Diseases of the spine in south american mummies.
Neurosurgery. 2001;48(1):208-213.
https://academic.oup.com/neurosurgery/article/48/1/208/2748891. Accessed Apr 3, 2020. doi:
10.1097/00006123-200101000-00039.

2. Cave AJE, Demonstrator A. The evidence for the incidence of tuberculosis in ancient egypt.
British Journal of Tuberculosis. 1939;33(3):142-152.
http://www.sciencedirect.com/science/article/pii/S0366085039800163. Accessed Apr 3, 2020.
doi: 10.1016/S0366-0850(39)80016-3.

3. History | world TB day | TB | CDC. https://www.cdc.gov/tb/worldtbday/history.htm. Updated
2019. Accessed Apr 3, 2020.

4. Tuberculosis. https://www.who.int/westernpacific/health-topics/tuberculosis. Accessed Apr 3,
2020.

5. Data & statistics | TB | CDC. https://www.cdc.gov/tb/statistics/default.htm. Updated 2020.
Accessed Apr 3, 2020.

6. Information, National Center for Biotechnology, Pike, U. S. National Library of Medicine
8600 Rockville, MD B, Usa 2. Treatment of tuberculosis patients. World Health Organization;
2008. https://www.ncbi.nlm.nih.gov/books/NBK310759/. Accessed Apr 3, 2020.

58

7. Mahajan R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int J Appl Basic
Med Res. 2013;3(1):1-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678673/. Accessed
Apr 3, 2020. doi: 10.4103/2229-516X.112228.

8. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant
tuberculosis: An update on disease burden, diagnosis and treatment. Respirology.
2018;23(7):656-673. Accessed Apr 3, 2020. doi: 10.1111/resp.13304.

9. Das S, Bhattacharjee O, Goswami A, Pal NK, Majumdar S. Arabinosylated
lipoarabinomannan (ara-LAM) mediated intracellular mechanisms against tuberculosis infection:
Involvement of protein kinase C (PKC) mediated signaling. Tuberculosis (Edinb).
2015;95(2):208-216. Accessed Apr 3, 2020. doi: 10.1016/j.tube.2014.11.007.

10. Hayashi JM, Luo C, Mayfield JA, et al. Spatially distinct and metabolically active membrane
domain in mycobacteria. PNAS. 2016;113(19):5400-5405. Accessed Apr 3, 2020.

11. Hayashi JM, Richardson K, Melzer ES, et al. Stress-induced reorganization of the
mycobacterial membrane domain. mBio. 2018;9(1). Accessed Apr 3, 2020. doi:
10.1128/mBio.01823-17.

12. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffé M. Direct visualization of the
outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol.
2008;190(16):5672-5680. Accessed Apr 3, 2020. doi: 10.1128/JB.01919-07.

13. Ito T, Hasegawa A, Hosokawa H, et al. Human Th1 differentiation induced by
lipoarabinomannan/lipomannan from mycobacterium bovis BCG tokyo-172. Int Immunol.

59

2008;20(7):849-860. https://academic.oup.com/intimm/article/20/7/849/694637. Accessed Apr
22, 2020. doi: 10.1093/intimm/dxn043.

14. Bansal-Mutalik R, Nikaido H. Mycobacterial outer membrane is a lipid bilayer and the inner
membrane is unusually rich in diacyl phosphatidylinositol dimannosides. PNAS.
2014;111(13):4958-4963. Accessed Apr 3, 2020.

15. Kalscheuer R, Palacios A, Anso I, et al. The mycobacterium tuberculosis capsule: A cell
structure with key implications in pathogenesis. Biochem J. 2019;476(14):1995-2016.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698057/. Accessed Apr 16, 2020. doi:
10.1042/BCJ20190324.

16. Hansmeier N, Albersmeier A, Tauch A, et al. The surface (S)-layer gene cspB of
corynebacterium glutamicum is transcriptionally activated by a LuxR-type regulator and located
on a 6 kb genomic island absent from the type strain ATCC 13032. Microbiology (Reading, Engl
). 2006;152(Pt 4):923-935. Accessed Apr 3, 2020. doi: 10.1099/mic.0.28673-0.

17. Hoischen C, Gura K, Luge C, Gumpert J. Lipid and fatty acid composition of cytoplasmic
membranes from streptomyces hygroscopicus and its stable protoplast-type L form. J Bacteriol.
1997;179(11):3430-3436. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179132/. Accessed
Apr 3, 2020.

18. Howlett R, Anttonen K, Read N, Smith MCM. Disruption of the GDP-mannose synthesis
pathway in streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes.
Microbiology (Reading, Engl ). 2018;164(4):614-624. Accessed Apr 3, 2020. doi:
10.1099/mic.0.000636.

60

19. Kovacevic S, Anderson D, Morita YS, et al. Identification of a novel protein with a role in
lipoarabinomannan biosynthesis in mycobacteria. J Biol Chem. 2006;281(14):9011-9017.
http://www.jbc.org/content/281/14/9011. Accessed Apr 3, 2020. doi: 10.1074/jbc.M511709200.

20. Morita YS, Sena CBC, Waller RF, et al. PimE is a polyprenol-phosphate-mannose-dependent
mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in
mycobacteria. J Biol Chem. 2006;281(35):25143-25155. Accessed Apr 3, 2020. doi:
10.1074/jbc.M604214200.

21. Rainczuk AK, Yamaryo-Botte Y, Brammananth R, et al. The lipoprotein LpqW is essential
for the mannosylation of periplasmic glycolipids in corynebacteria. J Biol Chem.
2012;287(51):42726-42738. http://www.jbc.org/content/287/51/42726. Accessed Apr 3, 2020.
doi: 10.1074/jbc.M112.373415.

22. Mishra AK, Alderwick LJ, Rittmann D, et al. Identification of an alpha(1-->6)
mannopyranosyltransferase (MptA), involved in corynebacterium glutamicum lipomanann
biosynthesis, and identification of its orthologue in mycobacterium tuberculosis. Mol Microbiol.
2007;65(6):1503-1517. Accessed Apr 3, 2020. doi: 10.1111/j.1365-2958.2007.05884.x.

23. Mishra AK, Krumbach K, Rittmann D, et al. Lipoarabinomannan biosynthesis in
corynebacterineae: The interplay of two α(1→2)-mannopyranosyltransferases MptC and MptD
in mannan branching. Mol Microbiol. 2011;80(5):1241-1259. Accessed Apr 3, 2020. doi:
10.1111/j.1365-2958.2011.07640.x.

61

24. Korkegian A, Roberts DM, Blair R, Parish T. Mutations in the essential arabinosyltransferase
EmbC lead to alterations in mycobacterium tuberculosis lipoarabinomannan. J Biol Chem.
2014;289(51):35172-35181. Accessed Apr 3, 2020. doi: 10.1074/jbc.M114.583112.

25. Zhang J, Amin AG, Hölemann A, Seeberger PH, Chatterjee D. Development of a plate-based
scintillation proximity assay for the mycobacterial AftB enzyme involved in cell wall arabinan
biosynthesis. Bioorg Med Chem. 2010;18(19):7121-7131. Accessed Apr 3, 2020. doi:
10.1016/j.bmc.2010.07.040.

26. Zhang J, Angala SK, Pramanik PK, et al. Reconstitution of functional mycobacterial
arabinosyltransferase AftC proteoliposome and assessment of decaprenylphosphorylarabinose
analogues as arabinofuranosyl donors. ACS Chem Biol. 2011;6(8):819-828. Accessed Apr 3,
2020. doi: 10.1021/cb200091m.

27. C. Rahlwes K. Regulation of lipomannan and lipoarabinomannan in
mycobacteria. University of Massachusetts Amhrest; 2018.

28. Hammes W, Schleifer KH, Kandler O. Mode of action of glycine on the biosynthesis of
peptidoglycan. J Bacteriol. 1973;116(2):1029-1053.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC285483/. Accessed Apr 3, 2020.

29. Mukherjee R, Chatterji D. Glycopeptidolipids: Immuno-modulators in greasy mycobacterial
cell envelope. IUBMB Life. 2012;64(3):215-225.
https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1002/iub.602. Accessed Apr 23, 2020. doi:
10.1002/iub.602.

62

30. Miyoshi-Akiyama T, Matsumura K, Iwai H, Funatogawa K, Kirikae T. Complete annotated
genome sequence of mycobacterium tuberculosis erdman. J Bacteriol. 2012;194(10):2770.
Accessed Apr 3, 2020. doi: 10.1128/JB.00353-12.

31. Stinear TP, Seemann T, Harrison PF, et al. Insights from the complete genome sequence of
mycobacterium marinum on the evolution of mycobacterium tuberculosis. Genome research.
2008;18(5):729-741. https://www.ncbi.nlm.nih.gov/pubmed/18403782. doi:
10.1101/gr.075069.107.

32. Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by
ethambutol in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53(10):41384146. Accessed Apr 3, 2020. doi: 10.1128/AAC.00162-09.

33. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol.
2006;62(5):1220-1227. Accessed Apr 3, 2020. doi: 10.1111/j.1365-2958.2006.05467.x.

34. Eagen WJ, Baumoel LR, Osman SH, Rahlwes KC, Morita YS. Deletion of PimE
mannosyltransferase results in increased copper sensitivity in mycobacterium smegmatis. FEMS
Microbiol Lett. 2018;365(6). https://academic.oup.com/femsle/article/365/6/fny025/4830098.
Accessed Apr 3, 2020. doi: 10.1093/femsle/fny025.

35. Rahlwes KC, Ha SA, Motooka D, et al. The cell envelope–associated phospholipid-binding
protein LmeA is required for mannan polymerization in mycobacteria. Journal of Biological
Chemistry Web site. http://www.jbc.org. Accessed Apr 3, 2020.

63

36. Perkowski EF, Zulauf KE, Weerakoon D, et al. The EXIT strategy: An approach for
identifying bacterial proteins exported during host infection. mBio. 2017;8(2). Accessed Apr 22,
2020. doi: 10.1128/mBio.00333-17.

37. Fukuda T, Matsumura T, Ato M, et al. Critical roles for lipomannan and lipoarabinomannan
in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. mBio. 2013;4(1):472.
Accessed Apr 3, 2020. doi: 10.1128/mBio.00472-12.

38. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob
Chemother. 1984;14 Suppl D:7-18. Accessed Apr 3, 2020. doi: 10.1093/jac/14.suppl_d.7.

39. Williamson R, Collatz E, Gutmann L. [Mechanisms of action of beta-lactam antibiotics and
mechanisms of non-enzymatic resistance]. Presse Med. 1986;15(46):2282-2289. Accessed Apr
3, 2020.

40. Gaynor M, Mankin AS. Macrolide antibiotics: Binding site, mechanism of action, resistance.
Curr Top Med Chem. 2003;3(9):949-961. Accessed Apr 3, 2020. doi:
10.2174/1568026033452159.

41. Morita YS, Sena CBC, Waller RF, et al. PimE is a polyprenol-phosphate-mannose-dependent
mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in
mycobacteria. J Biol Chem. 2006;281(35):25143-25155. Accessed Apr 3, 2020. doi:
10.1074/jbc.M604214200.

64

